The liquid biopsy has the potential to improve current clinical practice in oncology by providing real-time personalized information about a patient's disease status and response to treatment. In this study, we evaluated 161 peripheral blood (PB) samples that were collected around surgical resection from 47 metastatic colorectal cancer (mCRC) patients using the High-Definition Single Cell Assay (HDSCA) workflow. In conjunction with the standard circulating tumor cell (CTC) enumeration, cellular morphology and kinetics between time-points of collection were considered in the survival analysis. CTCs, CTC-Apoptotic, and CTC clusters were found to indicate poor survival with an increase in cell count from pre-resection to post-resection. This study demonstrates that CTC subcategorization based on morphological differences leads to nuanced results between the subtypes, emphasizing the heterogeneity within the CTC classification. Furthermore, we show that factoring in the time-point of each blood collection is critical, both for its static enumeration and for the change in cell populations between draws. By integrating morphology and time-based analysis alongside standard CTC enumeration, liquid biopsy platforms can provide greater insight into the pathophysiology of mCRC by highlighting the complexity of the disease across a patient's treatment.

Biomedical Center Faculty of Medicine in Pilsen Charles University 32300 Pilsen Czech Republic

Convergent Science Institute in Cancer Michelson Center for Convergent Bioscience Dornsife College of Letters Arts and Sciences University of Southern California Los Angeles CA 90089 USA

Department of Oncology and Radiotherapeutics Faculty of Medicine and University Hospital in Pilsen Charles University 32300 Pilsen Czech Republic

Department of Surgery Faculty of Medicine and University Hospital in Pilsen Charles University 32300 Pilsen Czech Republic

Zobrazit více v PubMed

Siegel R.L., Miller K.D., Goding Sauer A., Fedewa S.A., Butterly L.F., Anderson J.C., Cercek A., Smith R.A., Jemal A. Colorectal cancer statistics, 2020. CA Cancer J. Clin. 2020;70:145–164. doi: 10.3322/caac.21601. PubMed DOI

Fontana E., Nyamundanda G., Cunningham D., Tu D., Cheang M.C., Jonker D.J., Siu L.L., Sclafani F., Eason K., Ragulan C., et al. Intratumoral Transcriptome Heterogeneity Is Associated with Patient Prognosis and Sidedness in Patients with Colorectal Cancer Treated with Anti-EGFR Therapy from the CO.20 Trial. JCO Precis. Oncol. 2020;4:1152–1162. doi: 10.1200/PO.20.00050. PubMed DOI PMC

Suzuki Y., Ng S.B., Chua C., Leow W.Q., Chng J., Liu S.Y., Ramnarayanan K., Gan A., Ho D.L., Ten R., et al. Multiregion ultra-deep sequencing reveals early intermixing and variable levels of intratumoral heterogeneity in colorectal cancer. Mol. Oncol. 2016;11:124–139. doi: 10.1002/1878-0261.12012. PubMed DOI PMC

National Comprehensive Cancer Network Colon Cancer (Version 2.2021) [(accessed on 1 June 2021)]. Available online: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.

Van Cutsem E., Cervantes A., Nordlinger B., Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014;25((Suppl. 3)):iii1–iii9. doi: 10.1093/annonc/mdu260. PubMed DOI

Robson M., Im S.-A., Senkus E., Xu B., Domchek S.M., Masuda N., Delaloge S., Li W., Tung N., Armstrong A., et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N. Engl. J. Med. 2017;377:523–533. doi: 10.1056/NEJMoa1706450. PubMed DOI

Parker C., Castro E., Fizazi K., Heidenreich A., Ost P., Procopio G., Tombal B., Gillessen S. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2020;31:1119–1134. doi: 10.1016/j.annonc.2020.06.011. PubMed DOI

Hendricks A., Brandt B., Geisen R., Dall K., Röder C., Schafmayer C., Becker T., Hinz S., Sebens S. Isolation and enumeration of ctc in colorectal cancer patients: Introduction of a novel cell imaging approach and comparison to cellular and molecular detection techniques. Cancers. 2020;12:2643. doi: 10.3390/cancers12092643. PubMed DOI PMC

Souza e Silva V., Chinen L.T.D., Abdallah E.A., Damascena A., Paludo J., Chojniak R., Dettino A.L.A., Lopes de Mello C.A., Alves V.S., Fanelli M.F. Early detection of poor outcome in patients with metastatic colorectal cancer: Tumor kinetics evaluated by circulating tumor cells. OncoTargets Ther. 2016;9:7503–7513. doi: 10.2147/OTT.S115268. PubMed DOI PMC

Aggarwal C., Meropol N.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., Picus J., Morse M.A., Mitchell E., et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann. Oncol. 2012;24:420–428. doi: 10.1093/annonc/mds336. PubMed DOI

Arrazubi V., Mata E., Antelo M.L., Tarifa A., Herrera J., Zazpe C., Teijeira L., Viudez A., Suarez J., Hernández I., et al. Circulating Tumor Cells in Patients Undergoing Resection of Colorectal Cancer Liver Metastases. Clinical Utility for Long-Term Outcome: A Prospective Trial. Ann. Surg. Oncol. 2019;26:2805–2811. doi: 10.1245/s10434-019-07503-8. PubMed DOI

Baek D.H., Kim G.H., Song G.A., Han I.S., Park E.Y., Kim H.S., Jo H.J., Ko S.H., Park D.Y., Cho Y.-K. Clinical Potential of Circulating Tumor Cells in Colorectal Cancer: A Prospective Study. Clin. Transl. Gastroenterol. 2019;10:e00055. doi: 10.14309/ctg.0000000000000055. PubMed DOI PMC

Tsai W.-S., Hung W.-S., Wang T.-M., Liu H., Yang C.-Y., Wu S.-M., Hsu H.-L., Hsiao Y.-C., Tsai H.-J., Tseng C.-P. Circulating Tumor Cell Enumeration for Improved Screening and Disease Detection of Patients with Colorectal Cancer. Biomed. J. 2020 doi: 10.1016/j.bj.2020.09.006. PubMed DOI PMC

Hashimoto M., Tanaka F., Yoneda K., Takuwa T., Kuroda A., Matsumoto S., Okumura Y., Kondo N., Tsujimura T., Nakano T., et al. The clinical value of circulating tumour cells (CTCs) in patients undergoing pulmonary metastasectomy for metastatic colorectal cancer. J. Thorac. Dis. 2018;10:1569–1577. doi: 10.21037/jtd.2018.03.05. PubMed DOI PMC

Chu H.-Y., Yang C.-Y., Yeh P.-H., Hsu C.-J., Chang L.-W., Chan W.-J., Lin C.-P., Lyu Y.-Y., Wu W.-C., Lee C.-W., et al. Highly Correlated Recurrence Prognosis in Patients with Metastatic Colorectal Cancer by Synergistic Consideration of Circulating Tumor Cells/Microemboli and Tumor Markers CEA/CA19-9. Cells. 2021;10:1149. doi: 10.3390/cells10051149. PubMed DOI PMC

Allard W.J., Matera J., Miller M.C., Repollet M., Connelly M.C., Rao C., Tibbe A.G.J., Uhr J.W., Terstappen L.W.M.M. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 2004;10:6897–6904. doi: 10.1158/1078-0432.CCR-04-0378. PubMed DOI

Cohen S.J., Punt C.J.A., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., Picus J., Morse M., Mitchell E., Miller M.C., et al. Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients with Metastatic Colorectal Cancer. J. Clin. Oncol. 2008;26:3213–3221. doi: 10.1200/JCO.2007.15.8923. PubMed DOI

US Food and Drug Administration . 510(k) Summary Cellsearch® Circulating Tumor Cell Kit. US Food and Drug Administration; Washington, DC, USA: 2007.

Marrinucci D., Bethel K., Kolatkar A., Luttgen M.S., Malchiodi M., Baehring F., Voigt K., Lazar D., Nieva J.J., Bazhenova L., et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys. Biol. 2012;9:016003. doi: 10.1088/1478-3975/9/1/016003. PubMed DOI PMC

Rodríguez-Lee M., Kolatkar A., McCormick M., Dago A.D., Kendall J., Carlsson N.A., Bethel K., Greenspan E.J., Hwang S.E., Waitman K.R., et al. Effect of Blood Collection Tube Type and Time to Processing on the Enumeration and High-Content Characterization of Circulating Tumor Cells Using the High-Definition Single-Cell Assay. Arch. Pathol. Lab. Med. 2018;142:198–207. doi: 10.5858/arpa.2016-0483-OA. PubMed DOI PMC

Shishido S.N., Welter L., Rodriguez-Lee M., Kolatkar A., Xu L., Ruiz C., Gerdtsson A.S., Restrepo-Vassalli S., Carlsson A., Larsen J., et al. Preanalytical Variables for the Genomic Assessment of the Cellular and Acellular Fractions of the Liquid Biopsy in a Cohort of Breast Cancer Patients. J. Mol. Diagn. 2020;22:319–337. doi: 10.1016/j.jmoldx.2019.11.006. PubMed DOI PMC

Bethel K., Luttgen M.S., Damani S., Kolatkar A., Lamy R., Sabouri-Ghomi M., Topol S., Topol E., Kuhn P. Fluid phase biopsy for detection and characterization of circulating endothelial cells in myocardial infarction. Phys. Biol. 2014;11:016002. doi: 10.1088/1478-3975/11/1/016002. PubMed DOI PMC

Gerdtsson A.S., Thiele J.-A., Shishido S.N., Zheng S., Schaffer R., Bethel K., Curley S., Lenz H.-J., Hanna D.L., Nieva J., et al. Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer. Oncotarget. 2019;10:7016–7030. doi: 10.18632/oncotarget.27271. PubMed DOI PMC

Shishido S.N., Carlsson A., Nieva J., Bethel K., Hicks J.B., Bazhenova L., Kuhn P. Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. J. Transl. Med. 2019;17:294. doi: 10.1186/s12967-019-2035-8. PubMed DOI PMC

Welter L., Xu L., McKinley D., Dago A.E., Prabakar R.K., Restrepo-Vassalli S., Xu K., Rodriguez-Lee M., Kolatkar A., Nevarez R., et al. Treatment response and tumor evolution: Lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient. Cold Spring Harb. Mol. Case Stud. 2020;6:a005819. doi: 10.1101/mcs.a005819. PubMed DOI PMC

Ghatalia P., Smith C.H., Winer A., Gou J., Kiedrowski L.A., Slifker M., Saltzberg P.D., Bubes N., Anari F.M., Kasireddy V., et al. Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic. Front. Oncol. 2019;8:652. doi: 10.3389/fonc.2018.00652. PubMed DOI PMC

Grossman R.L., Dry J.R., Hanlon S.E., Johann D.J., Kolatkar A., Lee J.S.H., Meyer C., Salvatore L., Wells W., Leiman L. BloodPAC Data Commons for Liquid Biopsy Data. JCO Clin. Cancer Inform. 2021;5:479–486. doi: 10.1200/CCI.20.00179. PubMed DOI PMC

Grossman R., Abel B., Angiuoli S., Barrett J., Bassett D., Bramlett K., Blumenthal G., Carlsson A., Cortese R., DiGiovanna J., et al. Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium. Clin. Pharmacol. Ther. 2017;101:589–592. doi: 10.1002/cpt.666. PubMed DOI PMC

Febbo P.G., Martin A., Scher H.I., Barrett J.C., Beaver J.A., Beresford P.J., Blumenthal G.M., Bramlett K., Compton C., Dittamore R., et al. Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases. Clin. Pharmacol. Ther. 2020;107:730–734. doi: 10.1002/cpt.1747. PubMed DOI PMC

Godsey J.H., Silvestro A., Barrett J.C., Bramlett K., Chudova D., Deras I., Dickey J., Hicks J., Johann D.J., Leary R., et al. Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC’s Analytical Variables Working Group. Clin. Chem. 2020;66:1156–1166. doi: 10.1093/clinchem/hvaa164. PubMed DOI PMC

Dago A.E., Stepansky A., Carlsson A., Luttgen M., Kendall J., Baslan T., Kolatkar A., Wigler M., Bethel K., Gross M., et al. Rapid Phenotypic and Genomic Change in Response to Therapeutic Pressure in Prostate Cancer Inferred by High Content Analysis of Single Circulating Tumor Cells. PLoS ONE. 2014;9:e101777. doi: 10.1371/journal.pone.0101777. PubMed DOI PMC

Tie J., Cohen J.D., Wang Y., Christie M., Simons K., Lee M., Wong R., Kosmider S., Ananda S., McKendrick J., et al. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. JAMA Oncol. 2019;5:1710–1717. doi: 10.1001/jamaoncol.2019.3616. PubMed DOI PMC

Reinert T., Henriksen T.V., Christensen E., Sharma S., Salari R., Sethi H., Knudsen M., Nordentoft I.K., Wu H.-T., Tin A.S., et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients with Stages I to III Colorectal Cancer. JAMA Oncol. 2019;5:1124–1131. doi: 10.1001/jamaoncol.2019.0528. PubMed DOI PMC

Ruiz C., Li J., Luttgen M.S., Kolatkar A., Kendall J.T., Flores E., Topp Z., Samlowski W.E., McClay E., Bethel K., et al. Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. Phys. Biol. 2015;12:016008. doi: 10.1088/1478-3975/12/1/016008. PubMed DOI PMC

Malihi P.D., Graf R.P., Rodriguez A., Ramesh N., Lee J., Sutton R., Jiles R., Velasco C.R., Sei E., Kolatkar A., et al. Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer. Clin. Cancer Res. 2020;26:4143–4153. doi: 10.1158/1078-0432.CCR-19-4100. PubMed DOI PMC

Malihi P.D., Morikado M., Welter L., Liu S.T., Miller E.T., Cadaneanu R.M., Knudsen B.S., Lewis M.S., Carlsson A., Velasco C.R., et al. Clonal diversity revealed by morphoproteomic and copy number profiles of single prostate cancer cells at diagnosis. Converg. Sci. Phys. Oncol. 2018;4:015003. doi: 10.1088/2057-1739/aaa00b. PubMed DOI PMC

Gerdtsson E., Pore M., Thiele J.-A., Gerdtsson A.S., Malihi P.D., Nevarez R., Kolatkar A., Velasco C.R., Wix S., Singh M., et al. Multiplex protein detection on circulating tumor cells from liquid biopsies using imaging mass cytometry. Converg. Sci. Phys. Oncol. 2018;4:015002. doi: 10.1088/2057-1739/aaa013. PubMed DOI PMC

Gerdtsson A., Setayesh S., Malihi P., Ruiz C., Carlsson A., Nevarez R., Matsumoto N., Gerdtsson E., Zurita A., Logothetis C., et al. Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer. Cancers. 2021;13:1056. doi: 10.3390/cancers13051056. PubMed DOI PMC

Circulating Tumor Cell Kinetics and Morphology from the Liquid Biopsy Predict Disease Progression in Patients with Metastatic Colorectal Cancer Following Resection. [(accessed on 3 November 2021)]. Available online: https://pivot.usc.edu/pivot/CRC_Pilsen_Pivot_SN_20220118.html#%7B%22filters%22%3A%7B%7D%2C%22search%22%3Anull%2C%22sortBy%22%3A%22Timepoint%22%2C%22view%22%3A%22graph%22%7D. PubMed PMC

Defining A Liquid Biopsy Profile of Circulating Tumor Cells and Oncosomes in Metastatic Colorectal Cancer for Clinical Utility

Circulating Tumor Cell Kinetics and Morphology from the Liquid Biopsy Predict Disease Progression in Patients with Metastatic Colorectal Cancer Following Resection